SGMO News and Press, Sangamo Therapeutics Inc. From 04/02/24

2024-04-02 11:36:00 ET More on CRISPR Therapeutics Crispr Therapeutics: I'm Not Betting Against Gene Editing This Time (Upgrade) Crispr Therapeutics: Cautiously Optimistic CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conferen...

2024-03-22 08:21:15 ET More on Sangamo Therapeutics Sangamo Therapeutics GAAP EPS of -$0.34 misses by $0.08, revenue of $2.04M misses by $6.07M Sangamo stock soars 37% on updates for Fabry disease therapy Read the full article on Seeking Alpha For further det...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an aggregate of 24,761,905 shares of its common stock and pre-funded warrants to pur...

2024-03-13 15:30:02 ET H.C. Wainwright analyst issues BUY recommendation for SGMO on March 13, 2024 02:00PM ET. The previous analyst recommendation was Buy. SGMO was trading at $0.801 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curren...

2024-03-13 10:02:36 ET More on Sangamo Therapeutics Sangamo stock soars 37% on updates for Fabry disease therapy Seeking Alpha’s Quant Rating on Sangamo Therapeutics Historical earnings data for Sangamo Therapeutics Financial information for Sangamo Th...

Data from novel proprietary neurotropic adeno-associated virus (AAV) delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier (BBB) penetration in non-human primates (NHPs) following intravenous administration, with capsid-enabled delivery of zinc finger payloads targeting pri...

Novel AAV capsid engineered by Sangamo showed robust penetration of blood-brain barrier (BBB) and widespread transgene expression throughout brain in non-human primates (NHPs) following intravenous administration. Demonstrated industry-leading brain tropism and enrichment in NHPs, resulti...

SuRo Capital Corp. (SSSS) is expected to report for quarter end 2023-12-31 Enviva Inc. (EVA) is expected to report $-0.76 for Q4 2023 Jushi Holdings Inc. - Class B (Sub Voting) (JUSHF) is expected to report $-0.04 for Q4 2023 U Power Limited (UCAR) is expected to report for quarter en...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024. The Company will hold a conference call at 4:30 p....

Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...